Based on the aggregated intelligence of 180,000-plus investors participating in Motley Fool CAPS, the Fool's free investing community, biopharmaceutical company Geron (Nasdaq: GERN ) has received a distressing two-star ranking.
With that in mind, let's take a closer look at Geron's business and see what CAPS investors are saying about the stock right now.
||Menlo Park, Calif. (1990)
||CEO Dr. John Scarlett (since September 2011)
CFO Graham Cooper (since January 2012)
|Return on Equity (average, past 3 years)
||$118.2 million / $0
Sources: S&P Capital IQ and Motley Fool CAPS.
On CAPS, 8% of the 663 All-Stars who have rated Geron believe the stock will underperform the S&P 500 going forward.
Just yesterday, one of those bears, TSIF, touched on the stock's seemingly unsustainable valuation:
Geron Corp has doubled from it's June lows. ... A less toxic chemo drug delivery system seems promising, but also seems difficult to correlate and time consuming to study. ... Cash burn rate and cash position seem relatively strong although many biopharms sell into strength anyway. This might have made a good speculative up-play at $1.30 as insiders did. Overall, I'm not supporting the market cap at this stage.
If you want market-thumping returns, you need to protect your portfolio from any undue risk. Luckily, we've found another stock we are incredibly excited about -- excited enough to dub it "The Motley Fool's Top Stock for 2012." We have compiled a special free report for investors to uncover this stock today. The report is 100% free, but it won't be here forever, so click here to access it now.
Want to see how well (or not so well) the stocks in this series are performing? Follow the TrackPoisedTo CAPS account.